Endovia says FDA grants minor-use status for CannEpil canine bone cancer pain treatment
EDVA•Endovia Health Sciences and Lupvindol BioSciences received FDA CVM minor-use status for CannEpil to treat canine bone cancer pain, opening the MUMS conditional approval pathway. The companies scheduled an FDA pre-submission meeting for Nov. 19, 2026, and are targeting a potential U.S. veterinary launch in 2027, pending regulatory clearance.
1. Conditional approval pathway
Endovia Health Sciences and Lupvindol BioSciences received FDA Center for Veterinary Medicine minor-use status for CannEpil in canine bone cancer pain. The decision opens the MUMS conditional approval pathway, which may allow marketing before full effectiveness data if FDA conditions are met.
2. Next regulatory steps
The companies scheduled an FDA pre-submission meeting for Nov. 19, 2026, to align on studies, manufacturing and filings. U.S. manufacturing work is underway, with a potential veterinary launch targeted for 2027, pending regulatory clearance.
